Toggle Accessibility Tools

Molecular Discovery Grants

**Next Round of MDG - Summer 2021**


The Michigan State University Molecular Discovery Grants (MSU-MDG) have been established between the Department of Pharmacology & Toxicology and MSU Drug Discovery to provide pilot funding for accelerating the discovery and development of chemical technologies with applications for human health, animal health and agricultural use (max $30,000; average: $10,000- 15,000). The primary aim of these funds is to advance projects toward extramural funding or to the creation or development of intellectual property and commercialization.


Specific goals include:

• Assisting investigators in advancing their programs in the early phases of the discovery process with long-term commercialization in mind.

• Supporting early activities (e.g. screening) not readily funded by other sources.

• Providing additional data to support extramural grant applications.

• Aiding in the discovery or development of intellectual property.

• Accelerating therapeutics or diagnostics discovery and development programs


For more information, please contact:

Joseph Nichols, PhD - MSU Drug Discovery - Project Manager 


Molecular Discovery Grant Recipients

MDG Cycle
2/20 Jason Bazil, Ph.D. The search for Novel Mitoprotectants Against Reperfusion Injury
  Bryan Copple, Ph.D. Development of Machrphage Phenotypic Modulators as a Treatment for Liver Fibrosis
  Sean Crosson, Ph.D. High Throughput Screening for Host-Directed Antimicrobials Against Intracellular Brucella
  Kathleen Gallo, Ph.D. Mixed Lineage Kinase 3 Inhibitors for Glioblastoma
  Jian Hu, Ph.D. Developing Cell-based High Throughput Screening to Identify Inhibitors Against Pathogenic Fungal ZIP Metal Transporters
  Kin Sing Stephen Lee, Ph.D. Developing a sHE inhibitor with Improved Physicochemical Properties and CNS Penetration for Lupus
  Jeffrey MacKeigan, Ph.D Small Molecule Inhibitors of ULK1
  Aaron Odom, Ph.D. /Jetze Tepe, Ph.D. Exploration of in vivo Efficacy of Proteasome Inhibitors with Alternative Mechanisms
  Bryan Smith, Ph.D. Marophage-selective Nanotherapy to Treat Breast Cancer
5/19 Robert Abramovitch, Ph.D. Development of New Mycobacterium tuberculosis MmpL3 Inhibitors
  Bryan Copple, Ph.D. Modulation of Macrophage Phenotype to Treat Liver Fibrosis and Cirrhosis
  Andrea Doseff, Ph.D. / Karen Liby, Ph.D. Identifying Novel Strategies for the Treatment of Triple Negative Breast Cancer
  Erika Lisabeth, Ph.D. Identification of Small Molecule Modulators of the Serum Response Factor
  Dohun Pyeon, Ph.D. Developing Chemokine-based Novel Immunotherapies
  Christopher Waters, Ph.D.  Identifying Triclosan Analogs That Improve Synergy with Tobramycin to Eradicate Biofilms
9/17 Susan Conrad, Ph.D. Identifying Novel Strategies for Endocrine-resistant Metastatic ER+ Breast Cancer
  Aaron Odom, Ph.D. / Jetze Tepe, Ph.D. Exploration of Viability of Proteasome Inhibitors with Alternative Mechanisms
  Chrisopher Waters, Ph.D. Identifying Compounds That Enhance Biocide Killing of Waters System Biofilms
  Stephanie Watts, Ph.D. 5-HT7 Receptor Drug Discovery for Cardiovascular Disease
  Yong-Hui Zheng, Ph.D. High Throughput Screening of Novel Anti-HIV-1 Compounds
1/17 Robert Abramovitch Ph.D. Medicinal Chemistry Optimizations of Lead Compounds That Inhibit M. tuberculosis Persistence and drug tolerance
  Andre Bachmann Ph.D. Synthesis of Biological Evaluation of Phaseolotoxin-inspired ODC Inhibitors
  Jon Kaguni Ph.D. Targeted Drug Discovery to Identify Inhibitors of Bacterial DNA Replication
  Hao-Min Kuo Ph.D. Hyperphosphorylated tau Aggregation modulators as Candidates for Alzheimer's disease Therapeutics and Risk Factors
  Karen Liby, Ph.D. Synthesis and Characterization of New Rexinoids
  Jetze Tepe, Ph.D. Development of Drug-like TCH-165 Derivatives